Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
Soleno Therapeutics (NASDAQ: SLNO) has announced the pricing of its public offering of 2,352,941 shares of common stock at $85.00 per share, aiming to raise approximately $200 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to 352,941 additional shares.
The proceeds will primarily fund the commercialization of VYKATT� XR, their recently FDA-approved therapy for hyperphagia in Prader-Willi syndrome patients. Additional funds will support EU regulatory activities, research and development, and general corporate purposes. The offering, managed by Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor, and Oppenheimer, is expected to close around July 11, 2025.
Soleno Therapeutics (NASDAQ: SLNO) ha annunciato il prezzo della sua offerta pubblica di 2.352.941 azioni ordinarie a 85,00 $ per azione, con l'obiettivo di raccogliere circa 200 milioni di dollari di proventi lordi. La società ha inoltre concesso agli underwriter un'opzione di 30 giorni per acquistare fino a 352.941 azioni aggiuntive.
I proventi saranno principalmente destinati alla commercializzazione di VYKATT� XR, la loro terapia recentemente approvata dalla FDA per l'iperfagia nei pazienti con sindrome di Prader-Willi. Fondi aggiuntivi sosterranno le attività regolatorie nell'UE, la ricerca e sviluppo e scopi aziendali generali. L'offerta, gestita da Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor e Oppenheimer, dovrebbe concludersi intorno al 11 luglio 2025.
Soleno Therapeutics (NASDAQ: SLNO) ha anunciado el precio de su oferta pública de 2.352.941 acciones ordinarias a 85,00 $ por acción, con el objetivo de recaudar aproximadamente 200 millones de dólares en ingresos brutos. La compañÃa también ha otorgado a los suscriptores una opción de 30 dÃas para comprar hasta 352.941 acciones adicionales.
Los fondos se destinarán principalmente a financiar la comercialización de VYKATTâ„� XR, su terapia recientemente aprobada por la FDA para la hiperfagia en pacientes con sÃndrome de Prader-Willi. Fondos adicionales apoyarán las actividades regulatorias en la UE, la investigación y desarrollo, y propósitos corporativos generales. La oferta, gestionada por Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor y Oppenheimer, se espera que cierre alrededor del 11 de julio de 2025.
Soleno Therapeutics (NASDAQ: SLNO)ëŠ� 보통ì£� 2,352,941ì£�ë¥� 주당 85.00달러ì—� 공개 발행하여 ì•� 2ì–� 달러ì� ì´� 수ìµì� 목표ë¡� 한다ê³� 발표했습니다. 회사ëŠ� ë˜í•œ ì¸ìˆ˜ì¸ë“¤ì—게 30ì� ë™ì•ˆ 최대 352,941ì£�ë¥� 추가ë¡� 구매í•� ìˆ� 있는 옵션ì� 부여했습니ë‹�.
수ìµê¸ˆì€ 주로 최근 FDA 승ì¸ì� ë°›ì€ í”„ëž˜ë�-윌리 ì¦í›„êµ� 환ìžì� ê³¼ì‹ì¦� 치료ì � VYKATTâ„� XRì� ìƒì—…í™”ì— ì‚¬ìš©ë� ì˜ˆì •ìž…ë‹ˆë‹�. 추가 ìžê¸ˆì€ EU ê·œì œ 활ë™, 연구 개발 ë°� ì¼ë°˜ 기업 목ì ì� ì§€ì›í•˜ëŠ� ë� 사용ë©ë‹ˆë‹�. ì� 공모ëŠ� Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor ë°� Oppenheimerê°€ 관리하ë©�, 2025ë…� 7ì›� 11ì�ê²� 마ê°ë� ì˜ˆì •ìž…ë‹ˆë‹�.
Soleno Therapeutics (NASDAQ : SLNO) a annoncé le prix de son offre publique de 2 352 941 actions ordinaires à 85,00 $ par action, visant à lever environ 200 millions de dollars de produit brut. La société a également accordé aux souscripteurs une option de 30 jours pour acheter jusqu'à 352 941 actions supplémentaires.
Les fonds serviront principalement à financer la commercialisation de VYKATT� XR, leur thérapie récemment approuvée par la FDA pour l'hyperphagie chez les patients atteints du syndrome de Prader-Willi. Des fonds supplémentaires soutiendront les activités réglementaires dans l'UE, la recherche et développement ainsi que les besoins généraux de l'entreprise. L'offre, gérée par Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor et Oppenheimer, devrait se clôturer aux alentours du 11 juillet 2025.
Soleno Therapeutics (NASDAQ: SLNO) hat die Preisfestsetzung für sein öffentliches Angebot von 2.352.941 Stammaktien zu 85,00 USD pro Aktie bekanntgegeben, mit dem Ziel, etwa 200 Millionen USD Bruttoerlös zu erzielen. Das Unternehmen hat den Underwritern außerdem eine 30-tägige Option eingeräumt, bis zu 352.941 zusätzliche Aktien zu erwerben.
Die Erlöse werden hauptsächlich zur Kommerzialisierung von VYKATT� XR verwendet, ihrer kürzlich von der FDA zugelassenen Therapie gegen Hyperphagie bei Patienten mit Prader-Willi-Syndrom. Zusätzliche Mittel unterstützen die EU-Zulassungsaktivitäten, Forschung und Entwicklung sowie allgemeine Unternehmenszwecke. Das Angebot, verwaltet von Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor und Oppenheimer, soll voraussichtlich um den 11. Juli 2025 abgeschlossen werden.
- Recently received FDA approval for VYKATT XR as the first therapy for Prader-Willi syndrome hyperphagia
- Substantial capital raise of $200 million to support commercialization efforts
- Strong syndicate of investment banks supporting the offering
- Potential for European market expansion with regulatory activities planned
- Significant dilution for existing shareholders through new share issuance
- Stock offering priced at $85.00 may impact short-term trading performance
- No immediate revenue generation from commercialization efforts
- Additional capital needs possible for European expansion and R&D efforts
Insights
Soleno raises $200M to commercialize its newly FDA-approved Prader-Willi syndrome drug, strengthening its financial position for market launch.
Soleno Therapeutics has successfully priced a
The timing of this offering is strategically sound, coming just over three months after VYKATT� XR became the first approved therapy specifically addressing hyperphagia (excessive hunger) in Prader-Willi syndrome (PWS) - a rare genetic disorder affecting approximately 1 in 15,000 births. This approval represents a major milestone as PWS patients previously had no FDA-approved treatment options for this debilitating symptom.
The allocated use of proceeds reveals Soleno's comprehensive strategy: primarily funding VYKATT� XR's U.S. commercialization while simultaneously pursuing European regulatory approval and market development. This dual-market approach could significantly expand the revenue potential for their lead asset. The additional allocation toward research and development suggests Soleno aims to leverage its expertise in rare diseases beyond its initial indication.
The strong syndicate of underwriters (Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor, and Oppenheimer) indicates solid institutional interest in Soleno's commercial prospects. The inclusion of a 30-day option for underwriters to purchase an additional 352,941 shares suggests confidence in market demand for this offering. This financing provides Soleno the runway needed to execute its commercial launch effectively while advancing additional strategic initiatives.
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno)Â (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public ofÂ
Goldman Sachs & Co. LLC, Guggenheim Securities, TD Cowen, Cantor and Oppenheimer & Co. are acting as joint book-running managers for the public offering.
Soleno intends to use the net proceeds from this offering to fund the commercialization of VYKATTM XR, the first approved therapy to address hyperphagia in individuals with Prader-Willi syndrome, which was approved by the U.S. Food and Drug Administration on March 26, 2025. Soleno also intends to use the proceeds from the public offering to fund its regulatory and market development activities in the European Union and further research and development efforts, as well as general corporate purposes, which may include working capital, capital expenditures, other clinical trials, other corporate expenses and acquisitions of complementary products, technologies or businesses, though the company does not have agreements or commitments for any specific acquisitions at this time.
The shares are being offered pursuant to a registration statement on Form S-3ASR (File No. 333-276344), which became automatically effective upon filing with the Securities and Exchange Commission (the “SEC�) on January 2, 2024. The offering is being made solely by means of a written prospectus and a prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to this offering was filed with the SEC on July 10, 2025. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at [email protected]; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at [email protected]; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926 or by email at [email protected]; Cantor Fitzgerald & Co. by mail at Attention: Capital Markets, 110 East 59th Street, New York 10022 or by email at [email protected]; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the expected completion and timing of closing of the offering, the anticipated total gross proceeds from the offering, the anticipated use of proceeds therefrom, and all other statements that are not statements of historical facts. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, whether or not Soleno will be able to raise capital through the sale of securities or consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in Soleno's Annual Report on Form 10-K for the year ended December 31, 2024, Soleno’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, prior press releases and in other filings and reports filed with the SEC. The events and circumstances reflected in Soleno’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Soleno does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578Ìý
Media Contact:
